ZUG, Switzerland—Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a global biopharmaceutical company focused on innovations in neuro-ophthalmology and ophthalmology, has announced an asset purchase agreement with Accure Therapeutics, a clinical-stage, R&D-driven biopharmaceutical company based in Barcelona, Spain. Under the agreement and upon closing, Oculis will acquire all of Accure’s worldwide development and commercial rights to Privosegtor, an investigational neuroprotective drug candidate for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases, the announcement said. Currently, Privosegtor has not received regulatory approval for commercial use in any country.
The transaction consideration includes a $3.8 million (CHF 3.1 million) up-front cash payment at closing and up to 2,050,000 Oculis ordinary shares subject to lockup release over a period of up to two years or vesting upon achievement of development and regulatory milestones, the announcement said.
The pivot comes after Oculis’s legacy OCS-01 program in diabetic macular edema failed to meet primary endpoints in two phase 3 DIAMOND trials. Oculis said it will not pursue an FDA new drug application (NDA) for this indication.
“Acquiring Accure’s rights to Privosegtor is an important strategic milestone for Oculis. By terminating our legacy license agreement with Accure, we can secure global commercial rights to this unique, long-term asset at significantly reduced royalties as we build a leadership position in neuro-ophthalmology,” said Riad Sherif, MD, CEO of Oculis.
The company also announced that it is actively enrolling patients in the PREDICT-1 genotype-based registrational trial in dry eye disease (DED) evaluating Licaminlimab as a precision medicine treatment.
Oculis also reported results for the second quarter ended June 30, 2026. The company held cash, cash equivalents and short-term investments of CHF 228.3 million or $282.3 million as of June 30, 2026, compared with CHF 213.0 million or $268.7 million as of December 31, 2025. The increase reflects proceeds from sales of ordinary shares year-to-date under the company’s existing at-the-market offering program, offset by operating expenses, the announcement said.
Research and development expenses were CHF 15.3 million or $19.3 million for the three months ended June 30, 2026, compared with CHF 14.9 million or $18.1 million in the same period in 2025.
General and administrative expenses were CHF 8.6 million or $10.9 million for the three months ended June 30, 2026, compared with CHF 6.1 million or $7.4 million in the same period in 2025. The increase in operating expenses was primarily driven by headcount-related costs, including share-based compensation expenses, to support and execute the company’s development strategies, Oculis said.
Oculis’s net loss was CHF 38.8 million or $49.3 million for the six months ended June 30, 2026, compared with CHF 58.6 million or $67.9 million for the same period in 2025. The decrease was primarily due to the fair value gain on warrant liabilities in 2026 driven by decreased market value as well as a favorable foreign currency fluctuation, the company noted.
